Plexiform Lesions in Pulmonary Arterial Hypertension: Are We Getting Closer to Manage with More Patience and Rigor?
Overview
Overview
Journal
Arq Bras Cardiol
Specialty
Cardiology & Vascular Diseases
Date
2020 Oct 7
PMID
33027371
Citations
1
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant.
Jeican I, Inisca P, Gheban D, Anton V, Lazar M, Vica M J Pers Med. 2023; 13(2).
PMID: 36836513 PMC: 9961426. DOI: 10.3390/jpm13020279.
References
1.
Cahill E, Rowan S, Sands M, Banahan M, Ryan D, Howell K
. The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally. Exp Physiol. 2012; 97(6):796-806.
DOI: 10.1113/expphysiol.2012.065474.
View
2.
Dickinson M, Bartelds B, Borgdorff M, Berger R
. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 2013; 305(1):L1-14.
DOI: 10.1152/ajplung.00031.2013.
View
3.
Tuder R, Abman S, Braun T, Capron F, Stevens T, Thistlethwaite P
. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S3-S9.
DOI: 10.1016/j.jacc.2009.04.009.
View
4.
Phillips P, Long L, Wilkins M, Morrell N
. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2004; 288(1):L103-15.
DOI: 10.1152/ajplung.00095.2004.
View
5.
Gewehr D, Salgueiro G, de Noronha L, Kubrusly F, Kubrusly L, Coltro G
. Plexiform Lesions in an Experimental Model of Monocrotalin-Induced Pulmonary Arterial Hypertension. Arq Bras Cardiol. 2020; 115(3):480-490.
PMC: 9363102.
DOI: 10.36660/abc.20190306.
View